Upstate Active Clinical Trials

Study Title:

A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers

What is the purpose of the study? (in Layman's terms, please describe the study)

This study is being done to answer the following questions:
For patients with low grade serous ovarian cancer who have certain changes in the tumor DNA, can we help improve the amount of time before the cancer grows by treating with the combination of palbociclib and binimetinib?

For other patients with low grade serous ovarian cancer who have previously received a MEK inhibitor, can we improve outcomes by treating with palbociclib and binimetinib?

For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, can we improve the clinical outcome of survival without progression in patients who have certain changes in their tumor’s DNA by treating with palbociclib and binimetinib?

Upstate Institutional Review Board (IRB) Number:

2186865

Study/Protocol ID:

EAY191-A3

Study Phase:

Phase II

Patient Age Group:

Adults

Principal Investigator:

Rahul Seth, DO

What is involved if I participate?

• How long is the study?
  3 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  Office visits, laboratory blood tests, scans

Where will the study take place?

Upstate Cancer Center - Downtown campus
Upstate Cancer Center at Verona
Upstate Cancer Center at Oswego
Upstate Cancer Center - Gynecologic Oncology (Madison Irving Clinic)

Other Information:

As of 09/05/2024 cohort 4 is temporarily closed
As of 07/03/2024 cohort 3 is temporarily closed

ClinicalTrials.Gov ID:

NCT05554367

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Amelia Bell
Phone: 315-464-5777
Email: [email protected]

Return to Previous Page || Search Again